Back to Search
Start Over
Current Peptide and Protein Candidates Challenging HIV Therapy beyond the Vaccine Era.
- Source :
- Viruses (1999-4915); Oct2017, Vol. 9 Issue 10, p281, 14p
- Publication Year :
- 2017
-
Abstract
- Human immunodeficiency virus (HIV) is a causative agent of acquired immune deficiency syndrome (AIDS). Highly active antiretroviral therapy (HAART) can slow down the replication of HIV-1, leading to an improvement in the survival of HIV-1-infected patients. However, drug toxicities and poor drug administration has led to the emergence of a drug-resistant strain. HIV-1 immunotherapy has been continuously developed, but antibody therapy and HIV vaccines take time to improve its efficiency and have limitations. HIV-1-specific chimeric antigen receptor (CAR)-based immunotherapy founded on neutralizing antibodies is now being developed. In HIV-1 therapy, anti-HIV chimeric antigen receptors showed promising data in the suppression of HIV-1 replication; however, autologous transfusion is still a problem. This has led to the development of effective peptides and proteins for an alternative HIV-1 treatment. In this paper, we provide a comprehensive review of potent anti-HIV-1 peptides and proteins that reveal promising therapeutic activities. The inhibitory mechanisms of each therapeutic molecule in the different stages of the HIV-1 life cycle will be discussed herein. [ABSTRACT FROM AUTHOR]
- Subjects :
- HIV infections
THERAPEUTICS
AIDS vaccines
GENE therapy
DRUG resistance
IMMUNOTHERAPY
Subjects
Details
- Language :
- English
- ISSN :
- 19994915
- Volume :
- 9
- Issue :
- 10
- Database :
- Complementary Index
- Journal :
- Viruses (1999-4915)
- Publication Type :
- Academic Journal
- Accession number :
- 125972358
- Full Text :
- https://doi.org/10.3390/v9100281